Exact Sciences Corp. (EXAS), a provider of cancer screening and diagnostic tests, has witnessed a significant drop in its stock value over the past year, dropping from nearly $100 to approximately $40, largely due to growing investor concerns regarding increased competition in the cancer screening market.
The company's flagship product is the Cologuard test, the first and only FDA-approved non-invasive, multitarget stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.